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Abstract 
Veterinary clients may have trepidation about treating their pet with radiotherapy due to concerns 
about radiation side effects or repeated anaesthetics. The purpose of this study is to assess whether 
owners’ attitudes towards veterinary radiotherapy, including concerns over side effects, change 
during the course of treatment, and whether radiotherapy was perceived to affect pets’ quality of 
life. A prospective cohort study of clients from 2012-2015 was performed. Pets received palliative or 
definitive radiotherapy for various tumours. Clients completed questionnaires before, during and 
after radiotherapy. Questions assessed owner preconceptions before treatment, including side 
effect expectations, actual side effects experienced, and overall satisfaction with the process. In 
addition, at each time point the owners assessed their pet’s quality of life using a simple numerical 
scale. 49 patients were included. After completing treatment, owners were significantly less 
concerned about potential side effects of radiotherapy (P<0.001), side effects associated with repeat 
anaesthetics (P<0.001), and about radiotherapy in general (P<0.001). Quality of life did not show a 
significant change at any point during or after treatment. Following treatment, 94% reported the 
experience was better than expected and 100% supported the use of radiotherapy in pets. This is 
the first prospective study evaluating client attitudes and satisfaction before and after radiotherapy 
treatment in pets. The results indicate that radiotherapy is well tolerated, and the anxiety associated 
with radiotherapy is significantly alleviated after experiencing the process. These results will help 
veterinarians allay client concerns, and will hopefully lead to an increase in clients pursuing 
radiotherapy in pets. 
 
Introduction 
Radiotherapy is an expanding field of veterinary medicine. There has been significant growth in the 
number of veterinary centres providing radiotherapy in recent years, with one (US) survey finding a 
57% increase in the number of facilities providing veterinary radiotherapy between 2001 and 20101, 
as well as increased access to more advanced radiotherapy techniques. When presented as a 
treatment option, veterinary clients may have trepidation about treating their pet due to concerns 
about radiation side effects or repeated anaesthetics. Many of these concerns may be unfounded 
and possibly stem from a lack of experience and understanding of radiotherapy. 
 
Side effects associated with radiotherapy are dependent on the protocol used and the area being 
treated2, 3. Definitive intent protocols generally involve using smaller daily fractional doses more 
frequently (“conventionally fractionated”) and are typically associated with more acute side effects 
and fewer late radiation side effects. Conversely palliative protocols involve fewer but larger 
radiation doses separated temporally, often dosed weekly, (“hypofractionated”)  and are less likely 
to cause acute side effects however increase the chance of late side effects. Acute radiation side-
effects occur commonly and predictably using conventionally-fractionated protocols and occur in 
rapidly dividing tissues (skin, mucous membranes, gastrointestinal mucosa etc)2. They can usually be 
well managed with symptomatic treatments including oral antibiotics and anti-inflammatory 
corticosteroids and although severe in some cases, such effects are usually short-lived and rarely 
leave permanent damage.  Late radiation effects are uncommon, occurring in less than 5% of 
patients3. They are potentially serious and irreversible and are most commonly associated with 
hypofractionated protocols. Hypofractionated protocols are generally used in palliative settings 
where animals have a short predicted survival.  Late side effects generally develop 1-2 years 
following radiotherapy in tissues with slow turnover rates (eg bone, connective tissues, nerves etc). 
 
In the author’s experience there is still some reluctance to pursue radiotherapy amongst pet owners, 
perhaps due to prejudices stemming from a lack of understanding of the procedure or from prior 
experiences with radiotherapy in the human field, which can lead owners to believe the treatment 
will negatively impact their pet’s quality of life. Even amongst veterinarians, there is often a lack of 
understanding about what radiotherapy entails. In a previous survey of referring veterinarians 
concerning radiotherapy, only 57% had attended education programs for oncology or radiotherapy4. 
Veterinarians that had not attended education programs reported significantly less positive views 
regarding radiotherapy and estimated a significantly lower quality of life for patients undergoing 
radiotherapy. These veterinarians also reported significantly fewer situations where they believed 
radiotherapy was indicated than veterinarians which had attended oncologic or radiotherapy 
education programs4. This suggests that a lack of understanding and education about radiotherapy 
in pets in both veterinarians and owners could potentially be leading to pets not receiving 
appropriate treatment. 
 
Assessing quality of life in veterinary patients has been discussed in numerous studies5-9. 
Traditionally veterinary studies have inferred the impact of treatment on an animal’s quality of life 
from objective measurements of physical side effects. Recently however there has been an increase 
in specifically assessing pet quality of life in response to treatments. A 2017 article reviewed quality 
of life measurement in studies with cats or dogs receiving chemotherapy, and identified 11 studies 
which included quality of life measurements as part of the study 10. 
 
While there is no widely accepted definition of quality of life in veterinary patients, most agree that 
quality of life assessments encompass a continuum of an animal’s physical and mental well-being. As 
animals are unable to self-report, proxies are needed to assess their quality of life. Owners are 
frequently chosen as proxies as they are invariably the most familiar with the pet, including its 
normal behaviours and routines. Several studies have assessed the validity of using questionnaires 
with the owner of the pet acting as a proxy and these found that a simple questionnaire design is a 
useful tool to assess a pet’s quality of life6, 8.  
 
Numerous previous studies have assessed owner perceptions and patients’ quality of life in pets 
undergoing specific treatments for cancer4, 11-15. However only three previous studies have 
specifically addressed the use of radiotherapy in pets4, 14, 16. All three studies were retrospective 
cross-sectional studies using questionnaires or phone interviews completed between one month and 
eight years after completing radiotherapy. These studies relied on owners’ recollections of 
subjective perceptions and would have been susceptible to response bias. Patient quality of life was 
perceived to improve in 60-78% of cases in two studies 14, 16, and remain stable/improve in 87% of 
cases in the third study 4. In these same studies, 79-96% of clients responded that they would go 
through the process again. The majority of patients in these surveys received palliative radiotherapy, 
with one study 16 focussing solely on patients receiving palliative radiotherapy. This is likely to 
positively impact owners’ perceptions, as palliative radiotherapy is used to directly reduce morbidity 
associated with cancer, and so improve quality of life. 
 
No previous studies have assessed the owners’ attitudes towards radiotherapy prior to commencing 
treatment, and all studies have relied on memory to assess how the owners’ views had changed 
after the experience.  
 
The aim of the current study was to assess how clients’ attitudes regarding the use of radiotherapy 
in their pet changed over the course of treatment, using questionnaires completed 
contemporaneously throughout the treatment process. A secondary aim was to assess how the 
perceived quality of life changed over the course of treatment. Based on our subjective experience, 
we hypothesised that clients would become less anxious concerning possible complications after 
they had experienced the process, and that there would be no reduction in the perceived quality of 
life of their pets throughout the process. 
 
Materials and methods 
Ethical approval was given by the College of Medical, Veterinary and Life Sciences ethics committee 
at University of Glasgow in 2012. 
 
From April 2012 to April 2015, all owners of animals referred to the radiotherapy service at 
University of Glasgow Small Animal Hospital were invited to participate in the study if their animal 
was to be treated with radiotherapy as an out-patient. Questionnaires were completed at time of 
visit by owners while waiting for their animal to be treated or at a subsequent recheck appointment.  
For inclusion in the final analysis completion of both the first and final questionnaire and at least one 
inter-treatment questionnaire was required. Patients were assigned a number for the study and 
questionnaires were matched by number to blind the attending clinicians to responses. 
 
Radiotherapy protocols 
Radiotherapy was delivered using a Siemens OncorExpressionPlus linear accelerator with multileaf 
collimator using 6MV photons or an electron beam of varying energy as determined appropriate in 
the planning process. A variety of radiation protocols were used depending on the disease being 
treated and goals of therapy. Palliative-intent radiotherapy was defined as radiotherapy aiming to 
reduce morbidity associated with the disease, while definitive intent radiotherapy was defined as 
radiotherapy aiming to achieve a durable complete response.  
 
For microscopic residual disease around superficial surgical scars radiotherapy fields were manually 
planned to depth dose, using bolus as appropriate, including a 2-3cm margin surrounding the 
surgical scar and either a single or parallel-opposed fields.  The field coverage was planned to 95% 
total dose. For non-superficial structures of the head, neck and spine, patients were positioned in 
dorsal or sternal recumbency using personalised beam directional shell and vacuum cushions to 
immobilise the head along with larger vacuum cushions and/or radiography cradles as necessary to 
immobilise the body.  Position was verified using megavoltage electronic portal imaging, with 
alignment to skull or other anatomy prior to each dose of radiotherapy with a 2mm tolerance. 
Individualised treatment plans were generated using a 3D conformal computer planning software 
(Prowess Panther) and multiple coplanar beams with multileaf collimator, based on CT images of 
affected region (with contrast as necessary to view the lesion), and dosed to isocentre.  Gross 
tumour volume (GTV) was outlined using CT images and 0.5-1cm margin added for planned 
treatment/target volume (PTV) depending on tumour location and suspected/confirmed histological 
type. Radiation dose was conformed to the PTV as precisely as possible while attempting to exclude 
normal tissues. Ninety five percent of the total dose was prescribed to the planning target volume. 
Variations up to a maximum dose of 107% were considered acceptable. 
Anaesthesia 
Anaesthesias were performed by a board certified anaesthetist or anaesthesia resident. 
Anaesthetics typically lasted 20-45 minutes and animals were discharged once they were able to 
walk without assistance. Admission to discharge times were typically 60-90 minutes. 
 
Adverse effects 
Adverse effects were graded according to the Veterinary Radiation Therapy Oncology Group 
(VRTOG) radiotherapy side effects guidelines17. They were treated according to clinician preference, 
typically with oral anti-inflammatory prednisolone (usually 0.5mg/kg) and antibiotics. 
 
Questionnaire Design 
Four questionnaires (appendix 1) were designed to assess the owner’s perceptions of radiotherapy 
at different points during treatment: prior to commencing radiotherapy (“pre-treatment”); at the 
time of a treatment during the radiotherapy protocol (“mid-treatment”); at the time of the final 
radiotherapy treatment (“end-treatment”); and at the standard check-up appointment two to four 
weeks following the final radiotherapy treatment (“post-treatment”). To ensure all answers were 
scored from one (low impact of radiotherapy) to five (high impact of radiotherapy) in analysis, some 
negatively-phrased questions were included. The questionnaire was trialled on approximately 10 
clinicians and nurses within the University of Glasgow Small Animal Hospital prior to commencement 
and feedback was used to modify questions to minimise ambiguity. The attending clinicians were 
blinded to the responses during the radiotherapy treatment however the author was unblinded for 
data analysis in order to correlate responses with case records. 
 
The “pre-treatment” questionnaire was given to the owner at the initial consult when radiotherapy 
was first recommended for the patient or on the day of the first radiotherapy treatment. This 
questionnaire had 16 questions which included demographics, perceived quality of life, owner’s 
prior knowledge of radiotherapy, insurance status and questions to gauge owner’s perceptions and 
anxiety with regards to radiotherapy. 
 
The “mid-treatment” questionnaire was given at the half way point of treatment and had three 
questions assessing side effects of radiotherapy, side effects of concurrent medications used during 
radiotherapy and the perceived quality of life of the patient at this point.  The “end-treatment” 
questionnaire was the same design as the mid questionnaire but given on the final day of treatment. 
 
The “post-treatment” questionnaire was given at the check-up appointment between 2 and 4 weeks 
after the final radiotherapy treatment.  This included the questions in the mid and post 
questionnaires but also included comparable questions to the pre-treatment questionnaire to allow 
for direct comparison of attitudes before and after undergoing treatment 
 
Quality of life was measured using a simple numerical scale from 1-10, with one indicating quality of 
life could not be worse and 10 indicating quality of life could not be better. 
 
Statistical analysis 
Quality of life was measured at four time points and was analysed using an ANOVA with repeated 
measures test. Discrete statements (ordinal variables) were measured twice, before treatment and 
at follow up and were analysed using a Wilcoxon signed rank test. Responses were assigned a value 
(1-5) for analysis. Values of P < 0.05 were considered significant. 
 
Results 
128 patients were referred for radiotherapy during the study period (April 2012 – April 2015). Of 
these, the owners of 96 patients (74%) completed at least one questionnaire. 47/96 (49%) patients 
were excluded from the study as they did not complete both the first and last questionnaires. 49/96 
(51%) animals met the inclusion criteria; 42 patients had all four questionnaires completed and 
seven patients had three out of four questionnaires completed. The reason for non-completion of 
questionnaires was not recorded.  
 
Of the 128 patients treated in the study period, 17/128 (13%) did not complete the originally 
prescribed protocol. One of these patients was treated with two courses of radiotherapy during the 
study period. This patient successfully completed the first protocol however did not complete the 
second protocol due to disease related morbidity. 9/17 did not complete the protocol due to 
radiotherapy-unrelated factors (most commonly disease related morbidity or discovery of 
metastasis). 6/17 received reduced doses due to acute radiotherapy adverse events. 4/6 received a 
reduced number of fractions (and reduced overall dose) and 2/6 received a reduced overall dose 
however the planned number of fractions. All six of these patients suffered grade two adverse 
events (4/6 cutaneous, 2/6 mucous membrane). 2/6 of these patients were included in the study. 
2/17 stopped treatment due to acute gastrointestinal clinical signs and morbidity suspected to be 
due to undergoing general anaesthesia. 
 
Owners 
44/49 (90%) of patients undergoing treatment were insured and so had all or part of the cost of 
treatment paid for them; 30/44 (68%) reported they would have pursued radiotherapy even if not 
insured; 8/44 (18%) would not have pursued treatment without insurance and 6/44 (14%) did not 
submit a response to the question. 15/49 (31%) of owners reported having prior experience with 
radiotherapy. The vast majority (14/15) had experience from human medicine, with 7/15 having 
known someone who had been treated with radiotherapy, 6/15 working in human health care and 
one who had received treatment themselves. Only one owner had prior veterinary radiotherapy 
experience with a previous pet. 
 
Only 28/49 (57%) of respondents were aware radiotherapy was a treatment option available to pets 
prior to their pet becoming ill.  
 
Animals 
47 dogs and two cats were included in the study. Both cats were domestic short hairs. Of the dogs 
there were nine cross breeds, eight Labradors, five Staffordshire bull terriers, four golden retrievers, 
three labradoodles, two border collies and one each of cocker spaniel, Bichon frise, German 
shepherd dogs, rottweiler, shih tzu, Lhasa apso, saluki, Border terrier, boxer, weimaraner, bearded 
collie, lurcher, Shetland sheep dog, beagle, spinone and grey hound.  
 
The median age of animals was 8.8 years (range 1.3-14.2 years). There were 22 and six neutered and 
entire females respectively, and 15 and six neutered and entire males respectively.  
 
Tumours treated 
Tumours treated are listed in Table 1. 
 
Protocols  
47/49 animals were treated with a protocol that was considered definitive, while 2/49 animals were 
treated with a protocol that was considered palliative: a Labrador with oral melanoma treated with 
36Gy delivered weekly over four treatments of 9Gy and a Rottweiler with histiocytic sarcoma 
treated with 20Gy delivered daily over 5 treatments of 4Gy. 
 
Various protocols were used (table 1). The most common protocols used were 48Gy divided into 12 
fractions of 4Gy (n=23), 40Gy divided into 8 fractions of 5Gy (n=17), 48Gy divided into 16 fractions of 
3Gy (n=4) and five other protocols each used in a single animal. 
 
41/49 protocols used photons and 8/49 protocols used electrons. Electrons were used when 
superficial lesions were being treated and/or radiosensitive organs were located deep to the 
radiation field. 20 animals had gross disease and 29 had microscopic disease at the time of 
radiotherapy.  
 
Additional treatments 
31 patients had surgery as part of their treatment prior to radiotherapy (including one prophylactic 
enucleation to avoid ocular radiotherapy side effects). Radiotherapy was commenced two to three 
weeks post-surgery. 11 patients underwent chemotherapy as part of their treatment. 4/9 received 
intravenous chemotherapy concurrently with radiotherapy (three received vinblastine for mast cell 
tumour (MCT), one received carboplatin for anal sac adenocarcinoma), 1/9 received metronomic 
cyclophosphamide prior to radiotherapy and 6/9 received chemotherapy after radiotherapy 
(including two patients who received toceranib). One patient received a course of melanoma 
vaccination. 
 
Adverse effects  
Acute adverse events were recorded by the highest grade adverse effects reported at any point 
during/after treatment (for example if an animal had grade one skin adverse effects and grade two 
mucous membrane adverse effects it was recorded as a grade two). These are listed in Table 1. Nine 
animals had no adverse effects, 14 patients had grade one, 24 had grade two, and two had grade 
three. Location of all reported adverse effects were skin (n=37), mucous membrane (n=10), ocular 
(n=3), and lower gastrointestinal (n=1). 
 
Of the six animals that suffered no acute radiotherapy adverse effects, 5/6 were being treated with 
conventionally fractionated protocols for brain or spinal neoplasms and one was being treated 
palliatively with a hypofractionated protocol for histiocytic sarcoma. 
 
45/49 (92%) either “strongly agreed” or “agreed” with the statement “My pet did NOT have 
problems with repeat anaesthetics”. Only three owners responded “disagree” to the statement and 
none “strongly disagreed” or were neutral. One owner did not complete this question. 
 
Questionnaire answers 
 
Six questions present in the “pre-treatment” and “post-treatment” questionnaires were available for 
analysis. One question was excluded (“My partner/other family felt radiotherapy is the best option 
for our pet but I am unsure”) as the respondent was not standardised between visits, which made 
the results difficult to interpret. The remaining five questions were selected from the “pre-
treatment” and “post-treatment” questionnaires for analysis (Table 2 and 3). 
 
Quality of life measurement 
Quality of life was assessed for change in the 42 patients which had all four questionnaires 
completed. The quality of life measurement showed no significant change throughout the four time 
points measured during the treatment process (p=0.246). The median quality of life scores recorded 
in the “pre”, “mid”, “end” and “post” questionnaires were 8/10 (range 1-10), 8/10 (range 4-10), 8/10 
(range 4-10) and 9/10 (range 2-10).  
 
Post-treatment questions 
44/49 (90%) of respondents “agreed” or “strongly agreed” with the statement “My pet has not had 
excessive side effects from radiotherapy”. One client each disagreed and strongly disagreed with the 
statement. The remaining 3/49 respondents were “neutral”. 
 
47/49 (96%) of respondents “agreed” or “strongly agreed” with the statement “I am happy I chose 
to treat my pet with radiotherapy”. 2/49 respondents were neutral and none “disagreed” or 
“strongly disagreed” with the statement. 
 
Most owners (46/49, 94%) reported both that overall the radiotherapy experience was better than 
they expected, with 27 and 19 owners responding they “strongly agreed” and “agreed” with the 
statement “The radiotherapy experience was better than I expected”, respectively. Two respondents 
“disagreed” with the statement and one was “neutral”.  
 
Discussion 
To the authors’ knowledge this is the first study specifically evaluating the evolution of owners’ 
attitudes towards radiotherapy in pets before and after gaining first-hand experience of the 
treatment modality. The results clearly show that client anxiety regarding the side effects of 
radiotherapy and repeat anaesthetics decrease after experiencing the process. This indicates that 
much of the anxiety surrounding radiotherapy in pets may be based on incorrect preconceptions 
regarding the expected side effects from radiotherapy and repeat anaesthetic procedures. 
Importantly, most owners (46/49, 94%) reported that overall the radiotherapy experience was 
better than they expected, 44/49 (90%) reported that their pet did not experience excessive side 
effects, and no owners reported being unhappy with their choice to treat their pet with 
radiotherapy. 
 
Quality of life is of paramount concern for owners when making treatment decisions for pets. This is 
particularly true in oncologic cases where often the intent of treatment is not to cure the pet, but to 
extend good quality of life. Minimising side effects of treatment is therefore a primary goal. 
Surrogate assessment of quality of life in pets has been assessed in numerous studies5-9, and it is 
generally agreed that an animal’s owner is an appropriate surrogate. The current study utilised a 
simple numerical scale to estimate patient quality of life, which may not reflect the true quality of 
life of the patient. A more comprehensive questionnaire, such as the Canine Owner-Reported 
Quality of Life (CORQ) questionnaire18 may have allowed more accurate measurement of patient 
quality of life. The primary aim of the current study, however, was to assess owner perceptions, 
rather than actual quality of life, and therefore the more simple scale was chosen. The current study 
showed that undergoing radiotherapy did not significantly reduce quality of life in patients*, as 
judged by the pet’s owner.  
 
The current study is the first prospective study assessing client attitudes of radiotherapy in pets. It is 
also the first using multiple time points. The prospective study design and completion of 
questionnaires at the time of treatment will have reduced response bias which is likely to have been 
present in previous retrospective studies. Also, previous studies assessing owner perceptions of 
radiotherapy in pets had significantly higher proportions of animals receiving palliative radiotherapy 
4, 14, 16. As palliative radiotherapy is used to directly reduce the morbidity associated with cancer, we 
expect the owners of these patients to have reported relatively fewer adverse effects. This is 
because the benefits of the treatment (for example the reduction of pain associated with an 
osteosarcoma) will usually greatly outweigh the side effects of the treatment hence owners perceive 
a net improvement in their pet’s quality of life, even if they develop side effects.  
 In the current study 43/49 (88%) of patients developed side effects according to the VCOG-RT 
guidelines. Interestingly, only 2/49 (4%) of respondents perceived the side effects to be “excessive”.  
In previous studies, owners have reported their pets suffered adverse effects in 33-65% of cases, 
however also reported an improvement in quality of life in 60-78% 4, 16. This indicates that while side 
effects may be common, they are often perceived to be tolerable and not negatively impact the 
patients overall quality of life. 
 
A limitation of the study was the inclusion of four patients receiving chemotherapy concurrently 
during their radiotherapy protocols, as concurrent treatment may have impacted perceived side 
effects. However, none of the owners of these animals felt their pet suffered excessive side effects 
of treatment, ie none “disagreed” with the statement “My pet has NOT had excessive side effects 
from the radiotherapy treatment”, indicating that this would not have impacted the results. Only 
one of the owners of a pet receiving chemotherapy concurrently with radiotherapy (vinblastine for 
MCT) reported concerns about the side effects of radiotherapy following treatment (“disagreed” 
with the statement “I do NOT have any concerns about the side effects of treatment”). This patient 
had grade two skin side effects. 
 
Only 2/49 (4%) patients suffered grade 3 side effects. The first was a dog with an oral sarcoma which 
had its protocol reduced (from a planned total of 48Gy to a total of 46.9Gy) due to the development 
of grade three mucous membrane and grade two skin side effects which were deemed 
unacceptable. Interestingly this owner did not report that the side effects had been excessive, and in 
spite of these side effects at the end of treatment they responded that they felt it was the best 
treatment for their pet and were not apprehensive about the procedure, anaesthetics or potential 
radiotherapy side effects. The other patient was being treated for perianal fibrosarcoma with 
electron therapy and suffered grade three skin side effects. This owner reported having concerns 
about the side effects of radiotherapy and repeat anaesthetics following treatment, and was one of 
the two clients who did not “agree” or “strongly agree” that they were happy they chose to pursue 
radiotherapy. 
 
Only two owners reported that their pet suffered excessive side effects. Of these two cases, the first 
was a pituitary macroadenoma which suffered no adverse effects according to the VRTOG 
guidelines, making the questionnaire response difficult to explain. It is possible the negative 
responses were due to severe neurologic impairment due to the tumour or due to side effects from 
concurrent steroid use. The second patient had a perianal fibrosarcoma and, prior to radiotherapy, 
had post-operative complications including a draining-sinus. During radiotherapy this patient 
suffered grade 3 skin side effects and the owner also felt their pet did not tolerate repeated 
anaesthetics well.  
 
The majority of patients did not have problems with repeat anaesthetics, with only 3/49 perceiving 
that their pet had problems with repeat anaesthetics. Specific anaesthesia protocols were not 
included in the study and future investigations would required to determine if variables related to 
the anaesthesia (for example the choice of anaesthetic drugs) influences a pet’s perceived quality of 
life during treatment. 
 
Importantly, the vast majority of owners (46/49, 94%) reported that the radiotherapy experience 
was better than they expected. These results indicate that for most owners the procedure exceeds 
their expectations. Of the two respondents who reported the process was worse than expected (one 
other respondent was “neutral”), one was the previously mentioned dog with an oral sarcoma which 
suffered grade three side effects related to the oral location of the tumour. The other was a cat with 
central nervous system lymphoma which suffered significant disease-related neurological symptoms 
throughout treatment. Interestingly, in both the cases the owners still “strongly agreed” with the 
statements “I support the treatment of radiotherapy in pets” and “I feel radiotherapy was the best 
treatment for my pet”. This indicates that even when the experience was not as positive as 
expected, it was still considered worthwhile by the owners.  
 
In the current study the most common definitive radiotherapy protocol involved 12 fractions of 4 Gy 
(total of 48 Gy) given on a Monday, Wednesday, Friday basis. Other centres may use more 
hyperfractionated protocols (eg daily fractions) which may have more severe acute adverse events 
or anaesthetic complications which would impact on client attitudes. 
 
The current study is in agreement with previous studies 4, 14 in that the majority of clients reported 
that, if given the choice, they would go through radiotherapy again. This repeatable finding indicates 
that overall veterinary radiotherapy is considered beneficial and worthwhile to clients who have 
gone through the experience with pets with cancer. Crucially, all respondents in the current study 
supported the use of radiotherapy and none felt that radiotherapy was not the best treatment 
choice for their pet. 
 
This study has several limitations. Firstly the study naturally selected for clients willing to proceed 
with radiotherapy, a group that may have been more likely to report a positive view of the 
procedure. Also, not all questionnaires were completed by the same owner of patients, which may 
have introduced some variability in responses. Finally, only acute adverse events were included in 
the study (due to the period of sampling), so the impact of late effects on client attitudes was not 
assessed.  
 
Another limitation was the exclusion of patients that did not complete the full radiotherapy course, 
as they could not be included if they did not complete a “post-treatment”. Of the 17 patients which 
did not complete their originally prescribed radiotherapy course during the study period, only 6/17 
were due to acute radiotherapy adverse events. Of these six patients, two completed the 
questionnaires and were able to be included in the study, mitigating this limitation to some extent. 
Of the 11/17 patients which did not complete the radiotherapy protocol for non-radiotherapy 
adverse event related reasons, one patient was still able to be included in the study as they had 
previously completed a full course of radiotherapy, including questionnaires, successfully. 
 
Our study measured owner opinions while treatment was ongoing. Previous studies have used 
retrospective surveys which have numerous inherent limitations, particularly when measuring 
subjective responses. The current study showed a clear improvement in owner attitude towards 
radiotherapy in pets as their pet went through the procedure. 
 
Conclusion 
The results of this study indicate that radiotherapy is well tolerated by pets as judged by owners and 
the anxiety associated with undergoing radiotherapy and repeat anaesthetics is significantly 
alleviated after going through the process. These results will help veterinarians allay client concerns 
when discussing radiotherapy with clients, and will hopefully lead to an increase in clients pursuing 
radiotherapy for appropriate diseases in pets. 
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Table 1: Radiotherapy protocols used, diseases treated, and side effects. 
Protocol Electrons or 
Photons (6 
MeV) 
Disease Treated Disease Location Adverse Event Score 
(n) 
0 1 2 3 
48Gy over 
12 
treatments 
(Monday, 
Wednesda
y, Friday) 
(n=23) 
Photons FSA (n=2) Oral, extremity  1 1  
Carcinoma (n=4 Nasal (n=4)  2 2  
SCC (n=3) Tonsillar, oral, 
nasal 
1  2  
STS (n=6) Extremity (n=6)  2 4  
MCT (n=1) Extremity   1  
Chondrosarcom
a (n=1) 
Nasal   1  
Sarcoma (n=2) Retrobulbar, oral  1  1 
Electrons SCC (n=1) Extremity   1  
FSA (n=1) Perianal†    1 
STS (n=1) Facial†   1  
Pilomatrixoma 
(n=1) 
Extremity¶   1  
40Gy over 
8 
treatments 
(Monday, 
Friday) 
(n=17) 
Photons SCC (n=2) Pharyngeal, oral   2  
MCT (n=9) Extremity (n=8), 
muzzle 
1ǁ 5ǁǁ 3  
Infiltrative 
lipoma (n=1) 
Extremity 1    
STS (n=1) Extremity   1  
Electrons Adenocarcinom
a (n=1) 
Anal sac†   1ǁ  
Fibrosarcoma 
(n=1) 
Truncal‡   1  
MCT (n=2) Cutaneous 
muzzle§, axillary‡ 
 1 1  
48Gy over 
16  
treatments 
(n=4) 
Photons Glioma (n=2) Brain (n=2) 2    
Pituitary 
adenoma (n=2) 
Brain (n=2) 2    
48.6Gy 
over 18 
treatments 
(n=1) 
Photons Meningioma 
(n=1) 
Spinal 1    
39Gy over 
11 
treatments 
(n=1) 
Photons Fibrosarcoma 
(n=1) 
Oral   1  
36Gy over 
4 
treatments 
Photons Melanoma 
(n=1) 
Oral  1   
(weekly) 
(n=1) 
20GY over 
5 
treatments 
(n=1) 
Photons Histiocytic 
sarcoma (n=1) 
Extremity 1    
32Gy over 
8 
treatments 
(n=1) 
Photons Lymphoma 
(n=1) 
Brain  1   
SCC= squamous cell sarcoma, FSA= fibrosarcoma, STS= soft tissue sarcoma, TCC= transitional cell 
carcinoma, MCT= mast cell tumour 
†= 12 MeV, ‡= 10MeV, §= 8 MeV, ¶= 15 MeV, ǁ= denotes a single animal which received concurrent 
chemotherapy 
 
 
Table 2: Statements which showed a significant change pre- and post-treatment 
Statement Median response pre- and 
post-treatment 
P-value 
“I am NOT 
anxious/apprehensive about 
radiotherapy for my pet” 
Pre-treatment: “neutral” 
Post-treatment: “Strongly 
agree” 
0.000 
“I do NOT have any concerns 
about the repeat anaesthetics 
during radiotherapy 
treatment” 
Pre-treatment: “neutral” 
Post-treatment: “agree” 
0.000 
“I do NOT have any concerns 
about the side effects from the 
treatment” 
Pre-treatment: “neutral” 
Post-treatment: “agree” 
0.000 
 
Table 3: Statements which did not show a significant change pre- and post-treatment: 
Statement Median response pre- and 
post-treatment 
P-value 
“I support the treatment of 
radiotherapy in pets” 
Pre-treatment: “strongly 
agree” 
Post-treatment: “strongly 
agree” 
0.317 
“I feel radiotherapy is the best 
treatment for my pet” 
Pre-treatment: “strongly 
agree” 
Post-treatment: “strongly 
agree” 
1.000 
 
 
 
 
Appendix 1: Pre-treatment questionnaire 
Radiotherapy Questionnaire – Pre Treatment 
 
Questionnaire Number: 
 
Before your pet became ill, did you know that radiotherapy was available for pets? 
 
Yes    
 
No 
 
Have you previously had any experience of radiotherapy? 
 
 Yes 
 
 No 
 
If yes, how were you involved with radiotherapy previously? (Leave blank if you do not wish to answer.) 
 
 I have received treatment 
 
 A family member or close friend has received treatment 
 
 A previous pet has received treatment 
 
 I know a pet that has previously had treatment 
 
 I work/worked in human health care 
 
 I work/worked in animal health care 
 
Have you got pet insurance? 
 
 Yes 
 
 No 
 
If yes, would you have gone ahead with the radiotherapy treatment, if you did NOT have pet insurance? 
 
 Yes 
 
 No 
 
                                                                                                                        PTO 
Please Tick the box that indicates your opinion about the following statements. 
st Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
I support the treatment of radiotherapy 
in pets 
     
I feel radiotherapy is the best treatment 
for my pet 
     
I am NOT anxious/apprehensive about 
radiotherapy for my pet 
     
My partner/other family felt 
radiotherapy is the best option for our 
pet but I am unsure 
     
I do NOT have any concerns about the 
repeat anaesthetics during radiotherapy 
treatment 
     
I do NOT have any concerns about the 
side effects from the treatment 
     
Please indicate, using the numerical rating scale, how your pet’s quality of life was BEFORE it developed 
cancer? 
 
 1         2         3         4         5         6         7         8         9         10  
       QOL could                                                                                                           QOL could  
     not be worse                     not be better 
 
Please indicate using the numerical rating scale, how your pet’s quality of life is TODAY?  (AFTER being 
diagnosed with cancer) 
 
 1         2         3         4         5         6         7         8         9         10  
       QOL could                                                                                                           QOL could  
     not be worse                     not be better 
 
Please circle the correct description 
 
 Male          Female 
 
Age Group (please circle) 
  
 18 – 25 years     26 – 40 years     40 – 55 years     56 – 65 years     66 years +       
 
Please select the description which most closely matches where you live 
 
 City          Suburban          Rural          Unknown 
 
Appendix 2: Mid-treatment questionnaire 
Radiotherapy Questionnaire – Mid Point 
 
Questionnaire number 
 
Has your pet had any side effects from the MEDICATION taken during radiotherapy? (If your pet is not on 
medication please circle N/A)  
 
 Yes 
 
 No 
 
 N/A 
 
If yes what are these side effects? 
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________ 
 
 
Has your pet had any side effects from RADIOTHERAPY treatment so far? 
 
Yes 
 
  No 
 
If yes what are these side effects? 
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________ 
 
 
Please indicate using the numerical rating scale, how your pet’s quality of life was YESTERDAY? 
 
 1         2         3         4         5         6         7         8         9         10  
       QOL could                                                                                                           QOL could  
     not be worse                     not be better 
 
 
 
 
 
 
Appendix 3: End-treatment questionnaire 
Radiotherapy Questionnaire – End of Treatment 
 
Questionnaire number 
 
Has your pet had any side effects from the MEDICATION taken during radiotherapy since the last 
questionnaire? (Please describe even if they are the same as before) 
 
 Yes 
 
 No 
 
If yes what are these side effects? 
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________ 
 
 
Has your pet had any side effects from the RADIOTHERAPY treatment since the last questionnaire? (Please 
describe even if they are the same as before) 
 
 Yes 
 
 No 
 
If yes what are these side effects? 
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________ 
 
 
Please indicate using the numerical rating scale, how your pet’s quality of life was YESTERDAY? 
 
 1         2         3         4         5         6         7         8         9         10  
       QOL could                                                                                                           QOL could  
     not be worse                     not be better 
 
 
 
 
 
 
 
 
 Appendix 4: Post-treatment questionnaire 
Radiotherapy Questionnaire - Check up 
 
Questionnaire Number: 
 
Has your pet had any side effects from the MEDICATION since finishing radiotherapy? 
 
 Yes 
 
 No 
 
If yes what were these side effects? 
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________ 
 
Has your pet had any side effects from the RADIOTHERAPY treatment, since the last day of treatment? 
 
 Yes 
 
 No 
 
If yes what were these side effects? 
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________ 
 
 
Please indicate using the numerical rating scale, how your pet’s quality of life was YESTERDAY? 
 
 1         2         3         4         5         6         7         8         9         10  
       QOL could                                                                                                           QOL could  
     not be worse                     not be better 
 
 
 
 
 
 
 
 
 
                                                                                                                                PTO 
  
 
Please Tick the box that indicates your opinion about the following statements. 
 
st Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
During radiotherapy treatment my pet 
always had good days 
     
During radiotherapy treatment my pet 
had more good days than bad 
     
My pet did NOT have problems with the 
repeat anaesthetics when it came for 
treatment 
     
My pet has NOT had excessive side 
effects from the radiotherapy treatment 
     
I am happy I chose to treat my pet with 
radiotherapy 
     
The outcome of radiotherapy has been as 
expected 
     
The radiotherapy experience was as I 
expected 
     
The radiotherapy experience was better 
than I expected 
     
 
Please answer the following questions in respect to putting another pet through radiotherapy. 
 
st Strongly 
agree 
Agree Neutral Disagree Strongly 
disagree 
I support the treatment of radiotherapy 
in pets 
     
I feel radiotherapy was the best 
treatment for my pet 
     
I am NOT anxious/apprehensive about 
radiotherapy for my pet 
     
My partner/other family felt 
radiotherapy is the best option for our 
pet but I am unsure 
     
I do NOT have any concerns about the 
repeat anaesthetics during radiotherapy 
treatment 
     
I do NOT have any concerns about the 
side effects from the treatment 
     
 
 
 
 
 
